Table of Contents

October 18, 2005; 143 (8)

Articles

  • Inhaled Insulin Improves Glycemic Control When Substituted for or Added to Oral Combination Therapy in Type 2 Diabetes: A Randomized, Controlled Trial

    • Julio Rosenstock,
    • Bernard Zinman,
    • Liam J. Murphy,
    • Stephen C. Clement,
    • Paul Moore,
    • C. Keith Bowering,
    • Rosa Hendler,
    • Shu-Ping Lan,
    • and William T. Cefalu
    Ann Intern Med October 18, 2005 143:549-558

    The authors measured glycemic control with inhaled insulin alone or added to dual oral therapy in 309 patients who had no clinically significant respiratory disease. Combination therapy with inhaled insulin was more effective than monotherapy, but both therapies significantly reduced hemoglobin A1c levels. Hypoglycemia, mild weight gain, and mild cough were more frequent with inhaled insulin than with oral agents alone.

  • Exenatide versus Insulin Glargine in Patients with Suboptimally Controlled Type 2 Diabetes: A Randomized Trial

    • Robert J. Heine,
    • Luc F. Van Gaal,
    • Don Johns,
    • Michael J. Mihm,
    • Mario H. Widel,
    • Robert G. Brodows,
    • and for the GWAA Study Group*
    Ann Intern Med October 18, 2005 143:559-569

    Exenatide mimics a polypeptide hormone that coordinates insulin release with ingestion of food. The authors compared glycemic control with exenatide or insulin glargine. After 26 weeks, both exenatide and insulin glargine had reduced hemoglobin A1c level by 1.11%, showing that the two are comparable. Exenatide principally affected postprandial glucose, while insulin glargine affected fasting glucose. Nausea and vomiting were more common with exenatide.

  • Effect of a Second-Generation Venous Catheter Impregnated with Chlorhexidine and Silver Sulfadiazine on Central Catheter–Related Infections: A Randomized, Controlled Trial

    • Mark E. Rupp,
    • Steven J. Lisco,
    • Pamela A. Lipsett,
    • Trish M. Perl,
    • Kevin Keating,
    • Joseph M. Civetta,
    • Leonard A. Mermel,
    • David Lee,
    • E. Patchen Dellinger,
    • Michael Donahoe,
    • David Giles,
    • Michael A. Pfaller,
    • Dennis G. Maki,
    • and Robert Sherertz
    Ann Intern Med October 18, 2005 143:570-580

    This trial compared second-generation antiseptic-coated venous catheters with uncoated catheters in 384 and 393 patients, respectively. Antiseptic coating significantly reduced the frequency of bacterial colonization of the catheter (13.3 vs. 24.1 colonized catheters per 1000 catheter-days). Rates of bloodstream infection with antiseptic-coated catheters and conventional catheters were 0.42 per 1000 catheter-days and 1.24 per 1000 catheter-days, respectively. This difference was not statistically significant.

  • Brief Communication: Physical Abuse of Boys and Possible Associations with Poor Adult Outcomes

    • William C. Holmes and
    • Mary D. Sammel
    Ann Intern Med October 18, 2005 143:581-586

    The authors interviewed a random sample of 197 men living in inner-city neighborhoods. One hundred participants (51%) reported a history of childhood physical abuse, which was severe in half of the cases. A parent was the abuser in 73% of cases. Symptoms of depression and post-traumatic stress disorder were more common in men with a history of childhood physical abuse, even after adjustment for differences between them and men who were not abused.

Updates

  • Update in Oncology

    • Julie R. Brahmer
    Ann Intern Med October 18, 2005 143:587-592

    This Update in Oncology focuses on new treatments for 4 common tumors in patients: prostate cancer, non–small-cell lung cancer, breast cancer, and colorectal cancer. The hot topics in 2004 were docetaxel for prostate cancer and pemetrexed and epidermal growth factor receptor mutations for non–small-cell lung cancer. The major advance for breast cancer was the use of aromatase inhibitors for adjuvant treatment. For colorectal cancer, the major development was the outcome of the trials studying bevacizumab and cetuximab.

Perspectives

  • Combination Pharmacotherapy for Cardiovascular Disease

    • Combination Pharmacotherapy and Public Health Research Working Group*
    Ann Intern Med October 18, 2005 143:593-599

    Rather than screening for risk factors for cardiovascular disease (CVD), Wald and Law proposed that everyone take a “polypill” containing a statin, a diuretic, a β-blocker, an angiotensin-converting enzyme inhibitor, aspirin, and folic acid. This type of combination pharmacotherapy may prove to be efficacious, but may also have harms that outweigh the benefits in a population in which relatively few persons are destined to develop CVD.

Medicine and Public Issues

  • Impact of the Medicare Modernization Act on Low-Income Persons

    • Dawn E. Havrda,
    • Beth A. Omundsen,
    • William Bender,
    • and Mary Ann Kirkpatrick
    Ann Intern Med October 18, 2005 143:600-608

    The authors measured the impact of the Medicare Modernization Act of 2003 on medication expenditures by low-income Medicare recipients who qualify for pharmaceutical company assistance for obtaining medications. Medicare drug discount cards resulted in less savings than pharmaceutical company assistance programs.

Editorials

  • Treatment of Type 2 Diabetes Mellitus: A Weighty Enigma

    • Richard J. Comi
    Ann Intern Med October 18, 2005 143:609-610

    When an obese diabetic patient does not maintain glucose control, clinicians must decide if better control of glycemia is worth 10 pounds of weight gain. Why are we in this therapeutic dilemma? First, we have an incomplete mechanistic understanding of the pathophysiology of diabetes at the molecular level. Second, poor lifestyle choices continue to undo the benefits of treatment. In this issue, 2 articles describe potentially valuable new treatments that address these difficulties.

  • Exorcising Ghosts and Unwelcome Guests

    • Christine Laine and
    • Cynthia D. Mulrow
    Ann Intern Med October 18, 2005 143:611-612

    Ghosts and guests haunt medical journals. We don't usually notice them, but they occasionally rattle their chains to make us aware of their presence. A recent experience reminded us that authorship is not always what it seems, and so we reflect on practices that cast dark shadows across scientific publications: guest authoring and ghostwriting.

On Being a Doctor

  • A First Brush with Professional Courtesy

    • Jules Hirsch
    Ann Intern Med October 18, 2005 143:613

    A colleague once showed me a letter from the new financial manager of a distinguished academic hospital, warning all alumni that giving special assistance to fellow physicians or their families, sometimes called “professional courtesy,” could be too costly in these times of health care penury. I always considered the injunction of the Hippocratic Oath “to consider dear to me as my parents him who taught me this art” a good lesson in kindness to be shown to other physicians and their families. I shared my colleague's indignation and, as I considered the matter, remembered my first brush with professional courtesy.

Letters

  • Noninfectious Causes of Cellulitis

    • Michael Barza
    Ann Intern Med October 18, 2005 143:614

  • Cardiobacterium valvarum Endocarditis

    • Xiang Han
    Ann Intern Med October 18, 2005 143:614

  • The Effects of a Smoking Cessation Intervention on 14.5-Year Mortality

    • Milan C. Mathew
    Ann Intern Med October 18, 2005 143:614-615

  • The Effects of a Smoking Cessation Intervention on 14.5-Year Mortality

    • Gregory J. Bombassei
    Ann Intern Med October 18, 2005 143:615

  • The Effects of a Smoking Cessation Intervention on 14.5-Year Mortality

    • Nicholas R. Anthonisen
    Ann Intern Med October 18, 2005 143:615

  • The Risk for Myocardial Infarction with Cyclooxygenase-2 Inhibitors

    • Jeong A. Kim,
    • Youn Seon Choi,
    • Dokyung Yoon,
    • and Kyung Hwan Cho
    Ann Intern Med October 18, 2005 143:615-616

  • The Risk for Myocardial Infarction with Cyclooxygenase-2 Inhibitors

    • Michal R. Pijak,
    • Igor Huzicka,
    • and Frantisek Gazdik
    Ann Intern Med October 18, 2005 143:616-617

  • The Risk for Myocardial Infarction with Cyclooxygenase-2 Inhibitors

    • Ken Shinmura and
    • Roberto Bolli
    Ann Intern Med October 18, 2005 143:617

  • The Risk for Myocardial Infarction with Cyclooxygenase-2 Inhibitors

    • James M. Brophy,
    • Linda E. Lévesque,
    • and Bin Zhang
    Ann Intern Med October 18, 2005 143:617-618

  • Position Paper: Ethics Manual

    • Vijay Rajput
    Ann Intern Med October 18, 2005 143:618

  • Position Paper: Ethics Manual

    • William E. Golden and
    • Robert B. Doherty
    Ann Intern Med October 18, 2005 143:618

  • Index Case of Familial Adenomatous Polyposis Revealed by Congenital Hypertrophy of the Retinal Pigment Epithelium

    • Robert L. Holmes,
    • Saket K. Ambasht,
    • and Patrick S. Kelley
    Ann Intern Med October 18, 2005 143:618-619

  • The Digital Camera as a Clinical Tool

    • John J. Stern
    Ann Intern Med October 18, 2005 143:619-620

  • Prescribing Methadone as an Analgesic

    • Richard C. Dart,
    • George E. Woody,
    • and Herbert D. Kleber
    Ann Intern Med October 18, 2005 143:620

Medical Notices

  • Medical Notices

    Ann Intern Med October 18, 2005 143:0

Summaries for Patients

« Previous | Next Issue »

This Issue

October 18, 2005; 143 (8)
  1. Articles
  2. Updates
  3. Perspectives
  4. Medicine and Public Issues
  5. Editorials
  6. On Being a Doctor
  7. Letters
  8. Medical Notices
  9. Summaries for Patients

Search in this issue:

Current Issue

  1. November 17, 2009, 151 (10)
  1. Alert me to current issues